-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Benzinga·05/13/2026 13:48:00
Listen to the news
Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $35.